By Marco Bühren, Marc Hesse and Thilo Kaltenbach

The MedTech C(D)MO market is growing faster than the broader MedTech industry — at 8–9% per annum through 2030 — driven by structural outsourcing growth, supply chain regionalization, and rising regulatory demands. Roland Berger and William Blair provide the first holistic assessment to differentiate C(D)MO archetypes, identify margin drivers, and map M&A investment opportunities across seven high-priority segments. For C(D)MO leaders and investors, the report delivers a five-point winning framework and a practical guide to navigating the reopening deal market.

The MedTech contract development and manufacturing organization (C(D)MO) market is entering a new phase. After years of pandemic-related demand disruption, inventory destocking, and geopolitical turbulence, the market is normalizing—and accelerating. MedTech OEMs are concentrating spend on fewer, more capable external partners. Platform consolidation is intensifying. And the M&A market, after a period of slower activity, is reopening with a growing pipeline of transactions. For C(D)MO leaders and investors seeking to understand where value lies — and how to capture it — the timing for a rigorous market assessment has rarely been more important.

A market growing faster than MedTech itself

The global MedTech market is forecast to grow at 7% per annum through 2030. The MedTech C(D)MO market is expected to exceed this rate, growing at 8–9% annually, as OEMs continue to convert capital expenditure into variable cost by outsourcing design, manufacturing, and validation to specialist partners. This structural outsourcing shift is not cyclical — it reflects a fundamental change in how MedTech OEMs manage complexity, regulatory risk, and supply chain resilience.

Roland Berger and William Blair have analyzed seven MedTech segments most relevant to C(D)MOs, covering a combined market of USD 273 billion in 2025: IVD, cardiology, orthopedics, audiology, neurology, robotics, and drug delivery. Across these segments, the C(D)MO-specific market reached USD 46 billion in 2025. Growth is not uniform: robotics, drug delivery, and orthopedics are among the fastest growing for C(D)MOs, while robotics platforms, drug delivery devices, and IVD consumables offer the most attractive conditions for investors — combining large underlying markets, disproportionate C(D)MO growth, and active consolidation dynamics.

What separates winning C(D)MOs from the rest

Margins across the C(D)MO landscape range from approximately 7% to 24% EBITDA. This wide spread is not random — it reflects identifiable and replicable structural advantages. Metal specialists achieve the highest margins, at around 24% EBITDA, driven by bottleneck capabilities in processes such as nitinol manufacturing that OEMs struggle to qualify independently. European-headquartered C(D)MOs outperform their US peers, averaging around 17% EBITDA margins against 15%, benefiting from precision engineering strengths and cost structures that are proving commercially attractive amid geopolitical uncertainty and localization pressures. Specialized, niche-focused players consistently outperform generalists across size and segment categories.

The study maps four distinct C(D)MO archetypes — segment specialists, material specialists, hybrid capability platforms, and generalists — and identifies which success factors apply to each. Across all archetypes, Roland Berger's five-point winning framework identifies the characteristics that drive superior profitability and growth: a local, tariff-proof footprint proximate to key OEM customers; control of bottleneck capabilities where pricing power and customer stickiness concentrate; end-to-end value chain coverage from upstream design to downstream sterilization and packaging; focused portfolio positioning in complexity-driven segments; and automated, digitalized operations that improve yield, ramp-up speed, and cash conversion at scale.

OEM purchasing criteria reinforce this framework. Quality is non-negotiable and consistently the top selection criterion. Technical capabilities, delivery reliability, and regulatory expertise follow closely. Critically, value chain coverage, design and development support, and regulatory know-how are all gaining relevance as OEMs move toward fewer, more integrated partners with full accountability across the product development cycle.

M&A momentum is building

The C(D)MO deal market is reopening. MedTech OEM M&A volume surged to approximately USD 80 billion in 2025, with carve-outs and divestitures creating structural tailwinds for scaled C(D)MO platforms. A large cohort of private equity-backed platforms — many held beyond their typical investment windows — are approaching exit readiness as operating performance recovers and financing conditions stabilize. Deal flow is expected to accelerate into 2026 and 2027.

Premium transaction multiples, ranging from approximately 12x to 19.5x EV/EBITDA in recent transactions, are driven by a consistent set of attributes: a proven and resilient financial track record; a de-risked, diversified customer base with entrenched OEM relationships; exposure to structurally attractive medical applications; control of hard-to-qualify bottleneck processes; and a demonstrated acquisition platform with a track record of integrating add-on capabilities. The study's analysis of recent transactions — including scaled platform-on-platform deals such as Tecomet/Orchid and Resonetics/Resolution Medical — illustrates how the consolidation dynamic is playing out across metal and polymer segments.

Scale is now a precondition for competitive exit valuations. Sub-scale C(D)MOs that have not yet built sufficient capability breadth, geographic footprint, or OEM wallet share will find it increasingly difficult to compete for the most attractive programs — or to command premium multiples at exit. The full report provides a detailed investment guide to the C(D)MO M&A landscape, including segment-level opportunity maps, valuation corridor analysis, and practical guidance on platform development strategies.

This study was co-authored by Markus Müller, Matt Gilmore and Moritz Rottwinkel from William Blair .